
Can Rocket Pharmaceuticals Overcome Its Financial Burn Before Time Runs Out?
Rocket Pharmaceuticals faces a crucial moment in its stock market journey, balancing innovation against fiscal challenges. The company is at the forefront of gene therapies but remains unprofitable, with expenditures surpassing revenue. As of late 2024, Rocket’s cash reserve of $372 million